脈絡膜結核瘤嚴重類赫氏反應1例_Chinese Journal of Ocular Fundus Diseases

Authors：

宣懿 ,  劉衛 , 常青

復旦大學附屬眼耳鼻喉科醫院眼科, 上海 200031;

Corresponding?author：

劉衛, Email: bfgf14@aliyun.com

Keywords：

結核瘤; 脈絡膜腫瘤; 抗腫瘤藥，激素; 免疫抑制劑; 病例報告; 類赫氏反應

DOI：

10.3760/cma.j.cn511434-20220316-00149

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 宣懿, 劉衛, 常青. 脈絡膜結核瘤嚴重類赫氏反應1例. Chinese Journal of Ocular Fundus Diseases, 2022, 38(5): 400-402. doi: 10.3760/cma.j.cn511434-20220316-00149 Copy

1.	Cheung CM, Chee SP. Jarisch-Herxheimer reaction: paradoxical worsening of tuberculosis chorioretinitis following initiation of antituberculous therapy[J]. Eye (Lond), 2009, 23(6): 1472-1473. DOI: 10.1038/eye.2008.204.
2.	Al Majed SA. Study of paradoxical response to chemotherapy in tuberculous pleural effusion[J]. Respir Med, 1996, 90(4): 211-214. DOI: 10.1016/s0954-6111(96)90289-9.
3.	Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS[J]. Am J Respir Crit Care Med, 1998, 158(1): 157-161. DOI: 10.1164/ajrccm.158.1.9712001.
4.	Rathinam SR, Lalitha P. Paradoxical worsening of ocular tuberculosis in HIV patients after antiretroviral therapy[J]. Eye (Lond), 2007, 21(5): 667-668. DOI: 10.1038/sj.eye.6702662.
5.	Ganesh SK, Abraham S, Sudharshan S. Paradoxical reactions in ocular tuberculosis[J]. J Ophthalmic Inflamm Infect, 2019, 9(1): 19. DOI: 10.1186/s12348-019-0183-x.
6.	Yeh S, Sen HN, Colyer M, et al. Update on ocular tuberculosis[J]. Curr Opin Ophthalmol, 2012, 23(6): 551-556. DOI: 10.1097/ICU.0b013e328358ba01.
7.	Basu S, Das T. Pitfalls in the management of TB-associated uveitis[J]. Eye (Lond), 2010, 24(11): 1681-1684. DOI: 10.1038/eye.2010.110.
8.	Bansal R, Beke N, Sharma A, et al. Intravitreal bevacizumab as an adjunct in the management of a vascular choroidal granuloma[J/OL]. BMJ Case Rep, 2013, 2013: bcr2013200255[2013-09-06]. https://pubmed.ncbi.nlm.nih.gov/24014333/. DOI: 10.1136/bcr-2013-200255.
9.	Yilmaz T, Selcuk E, Polat N, et al. Choroidal tuberculoma showing paradoxical worsening in a patient with miliary TB[J]. Ocul Immunol Inflamm, 2015, 23(1): 97-99. DOI: 10.3109/09273948.2014.943350.
10.	Jain S, Bajgai P, Tigari B, et al. Bevacizumab for paradoxical worsening treatment adjunct in HIV patient with choroidal tuberculoma[J]. J Ophthalmic Inflamm Infect, 2016, 6(1): 42. DOI: 10.1186/s12348-016-0112-1.
11.	Arora A, Katoch D, Jain S, et al. Yellow subretinal lesions following initiation of antituberculosis therapy in a tubercular choroidal granuloma: a sign of paradoxical worsening?[J]. Ocul Immunol Inflamm, 2020, 30(1): 29-33. DOI: 10.1080/09273948.2020.1780272.
12.	Zhang M, Zhang J, Liu Y. Clinical presentations and therapeutic effect of presumed choroidal tuberculosis[J]. Retina, 2012, 32(4): 805-813. DOI: 10.1097/IAE.0b013e3182215b5e.
13.	Cheng VC, Yam WC, Woo PC, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients[J]. Eur J Clin Microbiol Infect Dis, 2003, 22(10): 597-602. DOI: 10.1007/s10096-003-0998-z.
14.	Agarwal A, Deokar A, Sharma R, et al. Longitudinal analysis of serum cytokine profile among. patients with tubercular multifocal serpiginoid choroiditis: a pilot study[J]. Eye (Lond), 2019, 33(1): 129-135. DOI: 10.1038/s41433-018-0157-5.
15.	McAllister WA, Thompson PJ, Al-Habet SM, et al. Rifampicin reduces effectiveness and bioavailability of prednisolone[J]. Br Med J (Clin Res Ed), 1983, 286(6369): 923-925. DOI: 10.1136/bmj.286.6369.923.
16.	Agrawal R, Testi I, Mahajan S, et al. Collaborative ocular tuberculosis study consensus guidelines on the management of tubercular uveitis-report 1: guidelines for initiating antitubercular therapy in tubercular choroiditis[J]. Ophthalmology, 2021, 128(2): 266-276. DOI: 10.1016/j.ophtha.2020.01.008.
17.	彭曉燕, 毛羽. 結核性葡萄膜炎診治困境及對策[J]. 眼科, 2019, 288(6): 325-327. DOI: 10.13281/j.cnki.issn.1004-4469.2019.05.002.Peng XY, Mao Y. The dilemma and countermeasure of diagnosis and treatment in tuberculous uveitis[J]. Ophthalmol CHN, 2019, 288(6): 325-327. DOI: 10.13281/j.cnki.issn.1004-4469.2019.05.002.
18.	Testi I, Agrawal R, Mehta S, et al. Ocular tuberculosis: where are we today?[J]. Indian J Ophthalmol, 2020, 68(9): 1808-1817. DOI: 10.4103/ijo.IJO_1451_20.
19.	Gupta V, Bansal R, Gupta A. Continuous progression of tubercular serpiginous-like choroiditis after initiating antituberculosis treatment[J]. Am J Ophthalmol, 2011, 152(5): 857-863. DOI: 10.1016/j.ajo.2011.05.004.
20.	Aggarwal K, Agarwal A, Deokar A, et al. Ultra-wide field imaging in paradoxical worsening of tubercular multifocal serpiginoid choroiditis after the initiation of anti-tubercular therapy[J]. Ocul Immunol Inflamm, 2019, 27(3): 365-370. DOI: 10.1080/09273948.2017.1373829.
21.	Ceylan OM, Durukan AH, Uysal Y, et al. Ocular complications of intravesicular BCG treatmentfor bladder carcinoma[J]. Ocul Immunol Inflamm, 2022, 30(1): 111-114. DOI: 10.1080/09273948.2020.1783323.
22.	Cugati S, Gilhotra JS, Lake S, et al. Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma[J]. Clin Exp Ophthalmol, 2014, 42(5): 494-495. DOI: 10.1111/ceo.12252.

1. Cheung CM, Chee SP. Jarisch-Herxheimer reaction: paradoxical worsening of tuberculosis chorioretinitis following initiation of antituberculous therapy[J]. Eye (Lond), 2009, 23(6): 1472-1473. DOI: 10.1038/eye.2008.204.
2. Al Majed SA. Study of paradoxical response to chemotherapy in tuberculous pleural effusion[J]. Respir Med, 1996, 90(4): 211-214. DOI: 10.1016/s0954-6111(96)90289-9.
3. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS[J]. Am J Respir Crit Care Med, 1998, 158(1): 157-161. DOI: 10.1164/ajrccm.158.1.9712001.
4. Rathinam SR, Lalitha P. Paradoxical worsening of ocular tuberculosis in HIV patients after antiretroviral therapy[J]. Eye (Lond), 2007, 21(5): 667-668. DOI: 10.1038/sj.eye.6702662.
5. Ganesh SK, Abraham S, Sudharshan S. Paradoxical reactions in ocular tuberculosis[J]. J Ophthalmic Inflamm Infect, 2019, 9(1): 19. DOI: 10.1186/s12348-019-0183-x.
6. Yeh S, Sen HN, Colyer M, et al. Update on ocular tuberculosis[J]. Curr Opin Ophthalmol, 2012, 23(6): 551-556. DOI: 10.1097/ICU.0b013e328358ba01.
7. Basu S, Das T. Pitfalls in the management of TB-associated uveitis[J]. Eye (Lond), 2010, 24(11): 1681-1684. DOI: 10.1038/eye.2010.110.
8. Bansal R, Beke N, Sharma A, et al. Intravitreal bevacizumab as an adjunct in the management of a vascular choroidal granuloma[J/OL]. BMJ Case Rep, 2013, 2013: bcr2013200255[2013-09-06]. https://pubmed.ncbi.nlm.nih.gov/24014333/. DOI: 10.1136/bcr-2013-200255.
9. Yilmaz T, Selcuk E, Polat N, et al. Choroidal tuberculoma showing paradoxical worsening in a patient with miliary TB[J]. Ocul Immunol Inflamm, 2015, 23(1): 97-99. DOI: 10.3109/09273948.2014.943350.
10. Jain S, Bajgai P, Tigari B, et al. Bevacizumab for paradoxical worsening treatment adjunct in HIV patient with choroidal tuberculoma[J]. J Ophthalmic Inflamm Infect, 2016, 6(1): 42. DOI: 10.1186/s12348-016-0112-1.
11. Arora A, Katoch D, Jain S, et al. Yellow subretinal lesions following initiation of antituberculosis therapy in a tubercular choroidal granuloma: a sign of paradoxical worsening?[J]. Ocul Immunol Inflamm, 2020, 30(1): 29-33. DOI: 10.1080/09273948.2020.1780272.
12. Zhang M, Zhang J, Liu Y. Clinical presentations and therapeutic effect of presumed choroidal tuberculosis[J]. Retina, 2012, 32(4): 805-813. DOI: 10.1097/IAE.0b013e3182215b5e.
13. Cheng VC, Yam WC, Woo PC, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients[J]. Eur J Clin Microbiol Infect Dis, 2003, 22(10): 597-602. DOI: 10.1007/s10096-003-0998-z.
14. Agarwal A, Deokar A, Sharma R, et al. Longitudinal analysis of serum cytokine profile among. patients with tubercular multifocal serpiginoid choroiditis: a pilot study[J]. Eye (Lond), 2019, 33(1): 129-135. DOI: 10.1038/s41433-018-0157-5.
15. McAllister WA, Thompson PJ, Al-Habet SM, et al. Rifampicin reduces effectiveness and bioavailability of prednisolone[J]. Br Med J (Clin Res Ed), 1983, 286(6369): 923-925. DOI: 10.1136/bmj.286.6369.923.
16. Agrawal R, Testi I, Mahajan S, et al. Collaborative ocular tuberculosis study consensus guidelines on the management of tubercular uveitis-report 1: guidelines for initiating antitubercular therapy in tubercular choroiditis[J]. Ophthalmology, 2021, 128(2): 266-276. DOI: 10.1016/j.ophtha.2020.01.008.
17. 彭曉燕, 毛羽. 結核性葡萄膜炎診治困境及對策[J]. 眼科, 2019, 288(6): 325-327. DOI: 10.13281/j.cnki.issn.1004-4469.2019.05.002.Peng XY, Mao Y. The dilemma and countermeasure of diagnosis and treatment in tuberculous uveitis[J]. Ophthalmol CHN, 2019, 288(6): 325-327. DOI: 10.13281/j.cnki.issn.1004-4469.2019.05.002.
18. Testi I, Agrawal R, Mehta S, et al. Ocular tuberculosis: where are we today?[J]. Indian J Ophthalmol, 2020, 68(9): 1808-1817. DOI: 10.4103/ijo.IJO_1451_20.
19. Gupta V, Bansal R, Gupta A. Continuous progression of tubercular serpiginous-like choroiditis after initiating antituberculosis treatment[J]. Am J Ophthalmol, 2011, 152(5): 857-863. DOI: 10.1016/j.ajo.2011.05.004.
20. Aggarwal K, Agarwal A, Deokar A, et al. Ultra-wide field imaging in paradoxical worsening of tubercular multifocal serpiginoid choroiditis after the initiation of anti-tubercular therapy[J]. Ocul Immunol Inflamm, 2019, 27(3): 365-370. DOI: 10.1080/09273948.2017.1373829.
21. Ceylan OM, Durukan AH, Uysal Y, et al. Ocular complications of intravesicular BCG treatmentfor bladder carcinoma[J]. Ocul Immunol Inflamm, 2022, 30(1): 111-114. DOI: 10.1080/09273948.2020.1783323.
22. Cugati S, Gilhotra JS, Lake S, et al. Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma[J]. Clin Exp Ophthalmol, 2014, 42(5): 494-495. DOI: 10.1111/ceo.12252.

Previous Article
18例內源性眼內炎患者的臨床特征和納米孔技術測序結果
Next Article
16號染色體父源單親二倍體致Bardet-Biedl綜合征1例

Chinese Journal of Ocular Fundus Diseases

脈絡膜結核瘤嚴重類赫氏反應1例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content